Compare AU
Compare VDHG vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Vanguard Diversified High Growth Funds (VDHG) and the BetaShares Global Healthcare ETF - Currency Hedged (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
VDHG | DRUG | |
|---|---|---|
Popularity | Medium | Low |
Pearlers invested | 8,530 | 63 |
Median incremental investment | $1,000.00 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,792.40 | $1,905.75 |
Average age group | 26 - 35 | 26 - 35 |
Key Summary
VDHG | DRUG | |
|---|---|---|
Strategy | Vanguard Diversified High Growth Index ETF (ASX: VDHG) seeks to track the weighted average performance of various ETFs it invests in before taking into account fees, expenses and taxes. The index doesn’t track companies directly. Instead, it invests in other ETFs. It acts as an ETF that tracks other ETFs. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | BHP Group Ltd. (3.79 %) Commonwealth Bank of Australia (3.03 %) CSL Ltd. (2.38 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Financials (17.35 %) Other (12.53 %) Information Technology (11.71 %) | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) |
Top 3 countries | United States (39.99 %) Australia (38.01 %) Japan (3.63 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 0.27 % | 0.57 % |
Key Summary
VDHG | DRUG | |
|---|---|---|
Issuer | Vanguard | BetaShares |
Tracking index | A17592 - 36% S&P - ASX300 - 26.5% MSCI Wrld ex-Aus - 16% MSCI Wrld ex-Aus Hdg to AUD - 6.5% MSCI Wrld ex-Aus Sml Cap - 5% MSCI EM Index - 3% Bloomberg AusBond Composite 0+ Yr Index - 7% Bloomberg Barclays Glb. Aggrt. Flt.-Adjstd and Scaled Index Hdg. to A | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.27 % | 0.57 % |
Price | $69.74 | $8.15 |
Size | $1.321 million | $182.401 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 5.54 % | 1.90 % |
Market | ASX | ASX |
First listed date | 22/11/2017 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
VDHG | DRUG | |
|---|---|---|
Popularity | Medium | Low |
Pearlers invested | 8,530 | 63 |
Median incremental investment | $1,000.00 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,792.40 | $1,905.75 |
Average age group | 26 - 35 | 26 - 35 |
Pros and Cons
VDHG | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
VDHG | DRUG |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |